APOL1-Mediated Kidney Disease (AMKD): Pathophysiology & Promise of Antisense Oligonucleotide (ASO) Therapy
Time: 9:00 am
day: Conference Day Two
Details:
- Discussing multiple proposed mechanisms of disease for AMKD
- Sharing Phase 1 data for APOL1 ASO Therapy
- Outlining AMKD Phase 2 study design challenges for APOL1 ASO Therapy
